Development of a Unique Rapid Test to Detect Anti-bodies Directed Against an Extended RBD of SARS-CoV-2 Spike Protein

FH-HES Universities of Applied Sciences

Authors

  • Larissa Brosi FHNW, School for Life Science, Hofackerstr. 30, CH-4132 Muttenz, Switzerland; BÜHLMANN Laboratories AG, Baselstr. 55, CH-4124 Schönenbuch, Switzerland
  • Thomas K. Villiger FHNW, School for Life Science, Hofackerstr. 30, CH-4132 Muttenz, Switzerland;, Email: thomas.villiger@fhnw.ch
  • Frank I. Bantleon BÜHLMANN Laboratories AG, Baselstr. 55, CH-4124 Schönenbuch, Switzerland;, Email: fb@buhlmannlabs.ch
  • Anna Melone BÜHLMANN Laboratories AG, Baselstr. 55, CH-4124 Schönenbuch, Switzerland
  • Marie-Eve Überschlag BÜHLMANN Laboratories AG, Baselstr. 55, CH-4124 Schönenbuch, Switzerland
  • Daniele Dolce BÜHLMANN Laboratories AG, Baselstr. 55, CH-4124 Schönenbuch, Switzerland
  • Cedric Giegelmann BÜHLMANN Laboratories AG, Baselstr. 55, CH-4124 Schönenbuch, Switzerland
  • Michael Gerspach BÜHLMANN Laboratories AG, Baselstr. 55, CH-4124 Schönenbuch, Switzerland
  • Lorin Dirscherl BÜHLMANN Laboratories AG, Baselstr. 55, CH-4124 Schönenbuch, Switzerland
  • Sherin Panikulam FHNW, School for Life Science, Hofackerstr. 30, CH-4132 Muttenz, Switzerland
  • Patrick Romann FHNW, School for Life Science, Hofackerstr. 30, CH-4132 Muttenz, Switzerland
  • Anna Weston FHNW, School for Life Science, Hofackerstr. 30, CH-4132 Muttenz, Switzerland
  • Eric Kübler FHNW, School for Life Science, Hofackerstr. 30, CH-4132 Muttenz, Switzerland
  • Christian-B. Gerhold BÜHLMANN Laboratories AG, Baselstr. 55, CH-4124 Schönenbuch, Switzerland;, Email: cbg@buhlmannlabs.ch

DOI:

https://doi.org/10.2533/chimia.2021.446

Keywords:

Antibodies, Lateral flow assay, Point-of-care, Rbd, Sars-cov-2

Abstract

Serological testing for antibodies directed against SARS-CoV-2 in patients may serve as a diagnostic tool to verify a previous infection and as surrogate for an elicited humoral immune response, ideally conferring immunity after infection or vaccination. Here, we present the recombinant expression of an extended receptor binding domain (RBD) of the SARS-CoV-2 Spike protein used as capture antigen in a unique rapid immunoassay to detect the presence of RBD binding antibodies with high sensitivity and specificity. As currently available vaccines focus on the Spike RBD as target, the developed test can also be used to monitor a successful immune response after vaccination with an RBD based vaccine.
CHIMIA Vol. 75 No. 05(2021): Colloidal Nanocrystals

Downloads

Published

2021-05-28

Issue

Vol. 75 No. 5 (2021): Colloidal Nanocrystals

Section

Columns, Conference Reports

Categories

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

[1]
L. Brosi, T. K. Villiger, F. I. Bantleon, A. Melone, M.-E. Überschlag, D. Dolce, C. Giegelmann, M. Gerspach, L. Dirscherl, S. Panikulam, P. Romann, A. Weston, E. Kübler, C.-B. Gerhold, Chimia 2021, 75, 446, DOI: 10.2533/chimia.2021.446.